FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome

By R. Q. Le, Liang Li, Weishi Yuan, S. Shord, Lei Nie, B. Habtemariam, D. Przepiorka, A. Farrell, R. Pazdur. The Oncologist, 2018

769 citations recorded by the source corpus.

This article summarizes key review findings that supported the approval of tocilizumab for treatment of severe or life‐threatening CAR T cell‐induced cytokine release syndrome.

Subfields: Hematology, Oncology

View Paper: https://www.semanticscholar.org/paper/5c517a9b3ab9262db2dcad7de4820e23ceb0e260

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. I. McInnes
2. Jennifer N. Brudno
3. J. Kochenderfer

In Oncology

1. J. Kochenderfer
2. Jennifer N. Brudno
3. I. McInnes
4. S. Gaffen

Citations in the corpus

• Interleukin‐6 in Covid‐19: A systematic review and meta‐analysis (2020, background): “21 ,22 Exploratory studies have suggested that IL-6 inhibition may be beneficial in patients with severe COVID-19 and, despite the absence of definitive evidence, very high drug cost, and unclear potential for harm, it has already been incorporated into COVID-19 management guidelines generated in…”
• Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) (2020, positive): “It has been approved for CRS and other inflammatory conditions related to IL-6 related inflammation, such as rheumatoid arthritis and juvenile idiopathic arthritis (215) (216) (217) (218) .”
• Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management (2018, background): “The IL-6 receptor antagonist tocilizumab has been widely used to treat severe CRS [7,11,14,26,29] and is FDA approved for this indication [76].”
• COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options (2020, methodology): “Therefore, its possible use in COVID-19 may be attractive to tackle CRS.”
• COVID-19: immunopathogenesis and Immunotherapeutics (2020, background): “Moreover, tocilizumab has been shown to be effective against cytokine release syndrome resulting from CART cell infusion against B cell acute lymphoblastic leukemia.(75) Blocking anti-human IL-6R by administering tocilizumab has been approved by China for COVID-19 treatment; a clinical trial (ChiCTR”
• Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality (2020, neutral): “study [49] included 3080 patients over 50 years old with more than one CVD risk factor for cardiovascular disease who met the diagnosis of active therapy [52] .”
• Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) (2020, neutral): “29 Whether tocilizumab can restore T cell counts in COVID-19 patients by suppressing IL-6 signaling remains uninvestigated.”